Which Cannabinoids Actually Lose Hemp Status on 12 November 2026?

Affiliate disclosure: My Cannabis Reviews earns a commission if you buy through some of the links on this page. It costs you nothing extra and it never decides what we write. Legal analysis on this page is editorial and is not influenced by any brand relationship. How we review.

Current status · last checked 20 September 2026. H.R. 6500, the stopgap funding bill, was signed into law on 2 September 2026 and is now Public Law 119-103. It moved most of the federal hemp rewrite from 12 November 2026 to 11 December 2026. It did not move all of it.

The Short Verdict

The federal hemp definition changes on two different dates, and which date applies to a given product depends on a distinction Congress wrote into the statute but never finished defining.

Cannabinoids that cannot be produced naturally by the cannabis plant at all lose federal hemp status on 12 November 2026, on the original schedule, with no extension. THC-O acetate is the clean example.

Everything else in the rewrite — including the 0.4 mg per-container cap and the shift from a delta-9-only test to a total-THC test that sweeps in THCA — moves to 11 December 2026.

The hard case is the middle category: cannabinoids that can occur in the plant but are made outside it, which is how most commercial delta-8 is produced. We read the statute as putting those in the 11 December group. That reading is contested, and we think you should know that rather than be handed a confident answer. Below we lay out both sides and show our work.

Separately — and this is the part almost every page on this subject gets wrong — the hemp definition and the Controlled Substances Act are two different questions. A product can be inside the December delay and still be something the DEA asserts is already a controlled substance. Those are not the same fight and they do not resolve together.

The two statutory categories, and the dates attached to them

The November 2025 appropriations law rewrote the Agricultural Marketing Act definition of hemp. It excluded two separate things. H.R. 6500 then delayed one exclusion and not the other. That is the whole mechanism.

The category language is not our paraphrase. Perkins Coie, writing on the original legislation, described the two exclusions as covering products containing "cannabinoids that are not capable of being naturally produced by the plant Cannabis sativa L." or "cannabinoids that may be naturally occurring in the cannabis plant but are synthesized or manufactured outside the plant." These are two distinct exclusions, not one. Everything below turns on that.

How H.R. 6500 actually works — and why it matters that it is not a date change

Nearly every summary of this law, including some written by lawyers, describes §2019 as "moving the hemp deadline to 11 December." That is a reasonable shorthand and it is not quite what the statute does. The operative sentence reads:

"Until December 11, 2026, the amendments made by section 781 of division B of Public Law 119-37 (7 U.S.C. 1639o note) shall only apply with respect to products described in paragraphs (1)(C)(ii)(I) and (1)(C)(iv)(I) of section 297A of the Agricultural Marketing Act of 1946 (7 U.S.C. 1639o) (as amended by such section 781)."

Read that again, because it is doing something specific. It does not postpone a date. It narrows what the 2025 rewrite reaches during the window between 12 November and 11 December, down to two named subclauses. Anything inside those two subclauses bites on 12 November. Everything else in the rewrite waits until 11 December.

So the entire question becomes: what is in subclause (I)?

Subclauses (1)(C)(ii)(I) and (1)(C)(iv)(I) are the same category applied to intermediate and final products respectively, and both read: "cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant." Subclause (II) — the one not carved in — covers cannabinoids that "(aa) are capable of being naturally produced by a Cannabis sativa L. plant; and (bb) were synthesized or manufactured outside the plant."

Converted delta-8 sits in subclause (II). Delta-8 occurs in cannabis, so it is capable of being naturally produced, whatever route a particular batch took. Subclause (II) is not among the two carved in for the November window. On the operative text, it is therefore not reached until 11 December.

Why the delta-8 date is contested anyway — and why we are showing our work

Most pages you will find on this question state a single confident date for delta-8. They disagree with each other. Here is the actual state of play.

The two candidate dates are 29 days apart. If you sell delta-8, that is a month of inventory. If you buy it, it is the difference between a product being federally reclassified before or after a date you may have planned around.

Our position, stated plainly: §2019 carves in two subclauses by number, and neither of them is the subclause covering converted cannabinoids. Delta-8 is capable of being naturally produced by cannabis, which puts it in subclause (II), which is not carved in. On the operative text we read that as 11 December.

The Congressional Research Service says something close to the same thing, and it is worth quoting because of who wrote it. In its report IF13136, in the version dated 17 August 2026 — before the bill was signed, so it speaks in the conditional — CRS described what would take effect on the earlier date this way: "Effective on November 12, 2026, would be the exclusion of intermediate and final hemp-derived cannabinoid products that contain cannabinoids that are not capable of being naturally produced by a cannabis plant (i.e., certain synthetic cannabinoids) from the definition of hemp." That tracks the subclause (I) language only. The same report lists the "capable of being naturally produced" but "synthesized or manufactured outside the plant" category as a separate exclusion. Two cautions: CRS never names delta-8 in connection with either date, so the delta-8 conclusion is ours and not theirs, and the report predates enactment.

Why we think the other reading arises: the sources landing on 12 November describe the split in general terms — natural cannabinoids get the reprieve, synthetics do not. That is a fair summary of what the 2025 rewrite was aiming at, and if you reason from the summary it lands you on 12 November for anything made by isomerisation. But §2019 does not use the word "synthetic," and it does not carve in by concept. It carves in by subclause number, and the subclause it names is the narrower "not capable of being naturally produced" category. The general characterisation and the cross-reference point in different directions, and the cross-reference is the part with legal effect.

What we are not going to do is tell you it is settled. Two practitioner sources read it the other way, and much of the retail-facing web has converged on 12 November for delta-8. We could be wrong. If you are making a commercial decision, plan for 12 November and treat 11 December as upside — the cost of being early is inventory timing, and the cost of being late is a product that has lost federal hemp status while it is sitting on your shelf.

The trap almost every other page falls into: two laws, two questions

This is the single most important thing on this page, so we are going to be blunt about it.

The Agricultural Marketing Act definition — the one the 2025 law rewrote and H.R. 6500 delayed — decides whether something is hemp. The Controlled Substances Act decides whether something is scheduled. They are different statutes answering different questions, and a product can be on the friendly side of one and the wrong side of the other.

The DEA's final rule of 4 May 2026 (91 Fed. Reg. No. 85, Docket DEA-1632) says, verbatim:

"To clarify further, tetrahydrocannabinols produced through chemical conversion, even when hemp derived are considered synthetically produced for purposes of the CSA, do not qualify as 'tetrahydrocannabinols in hemp' under the AIA."

Read carefully, that is not the DEA contradicting the December delay. It is the DEA saying that in its view conversion-produced THC was never lawful hemp THC in the first place — a CSA position, not an AMA one. Most commercial delta-8 is made by isomerising CBD, so the DEA's position reaches it regardless of how the hemp-definition question comes out.

So we will not write, and you should distrust any page that does write, "delta-8 is legal until 11 December." The accurate sentence is longer and less satisfying: the hemp-definition change reaches converted delta-8 on 11 December on the better reading of the statute, practitioners are split on that date, and the DEA separately maintains a contrary CSA position that is currently being litigated.

HHC: the honest answer is that nobody knows

We are not going to give you a date for HHC, because there isn't one to give.

The DEA's May 2026 rule calls HHC "a synthetic substance that is structurally related to tetrahydrocannabinols," and a February 2023 letter from Terrance Boos states that it "does not occur naturally in the cannabis plant and can only be obtained synthetically." That sounds decisive. It is not, for three reasons.

First, the statutory test is whether a cannabinoid is capable of being naturally produced. That is a capability question, not a how-was-this-batch-actually-made question, and the DEA was construing the Controlled Substances Act rather than the amended hemp definition. Second, Congress assigned the job of listing these cannabinoids to the FDA, which has published nothing. Third, the DEA's position is under active challenge in Bluestar Operations, LLC v. DEA (4th Cir.) and IHC Investments, Inc. v. DEA (9th Cir.); the Fourth Circuit denied a stay in June 2026, and as of mid-August the agency was arguing that the challengers lacked standing rather than defending the underlying science.

No court has ruled on whether HHC occurs naturally in cannabis. Anyone telling you confidently that HHC is banned on 12 November, or safe until 11 December, is guessing.

The reason all of this is a mess: the FDA missed its deadline by seven months

The 2025 law required the FDA to publish three lists — cannabinoids capable of being naturally produced by cannabis, THC-class cannabinoids naturally occurring in the plant, and other known cannabinoids with similar effects — plus separate guidance defining what counts as a "container" for the 0.4 mg limit.

All of it was due 10 February 2026. As of 20 September 2026 none of it has been published: 222 days late, with no timeline offered. FDA has issued no 2026 Federal Register rulemaking directed at cannabinoids; its only 2026 Federal Register discussion of delta-8 THC appears as a supporting example in the preamble to a proposed rule about something else, the 11 August 2026 GRAS proposed rule (Docket FDA-2025-N-3262). The FDA's cannabis landing page is still content-current as of 16 July 2024 and does not mention the lists or the new dates at all. Whitt Steineker of Bradley LLP, writing on 4 September 2026, put it plainly: "FDA also still hasn't published the list of covered cannabinoids or defined 'container.'" The Congressional Research Service — Congress's own research arm — flagged the same failure on 24 August 2026.

This is why the delta-8 question is contested at all. Because the lists do not exist, there is no federal categorisation of delta-8, delta-10, HHC or THC-O under the new definition. Every confident answer on the internet, ours included, is a reading of statutory text that the responsible agency was supposed to have resolved seven months ago.

What 11 December actually changes, beyond the category fight

Two changes on that date are not in dispute by anyone, and they are the ones most likely to affect what you can actually buy.

The 0.4 mg per-container cap. Not per serving — per container. The Congressional Research Service describes the limit as covering the combined total per container of total THC and other cannabinoids with similar effects, so it is broader than a THC-only reading suggests, and it defines container as the innermost packaging in direct contact with the product at retail. Taken at face value, this removes essentially every intoxicating hemp edible and drink currently sold from the federal hemp definition. A 10-pack of 5 mg gummies contains 50 mg. The cap is 0.4 mg. Note that "container" is also one of the terms the FDA was required to define and hasn't, so how it applies to multipacks and multi-serving bottles is genuinely unsettled.

Total THC replaces delta-9-only. The 2018 Farm Bill's 0.3% test measured delta-9 THC alone, which is what made high-THCA hemp flower viable — THCA is not delta-9 until it is heated. A total-THC standard counts THCA toward the limit. This is the change that ends the THCA flower and preroll market as it currently exists. If you buy THCA flower, this is your date, not the delta-8 argument.

Why 11 December is not a safe date either

Here is the wrinkle nobody selling you a stock-up guide will mention: 11 December 2026 is also the day the government runs out of money.

The same statute that moved the hemp deadline is a continuing resolution funding federal agencies through 11 December. The hemp date is no longer a hemp-policy date. It is attached to the next shutdown fight, and it will be renegotiated by the same people, under the same time pressure, as everything else in that bill.

That cuts both ways and we are not going to promise you an outcome in either direction. Representative Morgan Griffith (R-Va.), quoted by Roll Call on 24 August 2026, on how fragile the delay is: "The question is, if the Democrats decide to oppose the stopgap spending measure across the board, then there are probably enough 'no' votes to take that [delay] out." Representative Andy Harris (R-Md.), who opposes the delay: "Let's be clear: these are not harmless hemp products. They're intoxicating, unregulated, and widely available resulting in devastating numbers of children being hospitalized." Jonathan Miller of the US Hemp Roundtable described himself only as "cautiously optimistic." Bradley LLP, on 4 September, rated another short-term extension the likeliest of four scenarios while noting that "a post-election Congress approaching a lame-duck session is always unpredictable."

Plan for the deadline holding. Do not plan on another extension, and do not assume there won't be one.

There is also a bill that would repeal the rewrite outright rather than delay it — H.R. 9830, the Lawful Hemp Protection Act — but it has had no committee action since it was introduced on 22 July 2026, and it would not save THCA flower either. We go through what it would and would not do in our H.R. 9830 explainer.

How we got here, for the record

On 12 November 2025, a provision buried in an appropriations bill rewrote the federal definition of hemp, with a one-year runway to 12 November 2026.

On 8 August 2026, the Senate passed a stopgap containing the one-month delay, 90–6 (Roll Call Vote 228). Earlier that morning, the Senate voted 61–32 to table an amendment from Senator Ted Budd (R-N.C.) that would have struck the delay outright (S.Amdt. 6747, Vote 227). Twenty-one of the 32 votes against tabling were Republicans. Tabling the Budd amendment is what preserved the December date — Budd is a proponent of the earlier ban, not of the industry, and pages describing that vote the other way around have it backwards.

The House passed the bill 370–48 on 1 September 2026, on a motion to suspend the rules and concur in the Senate amendments (House Roll Call 286). The President signed it on 2 September 2026, and it is now Public Law 119-103. Per the White House record: H.R. 6500 "includes a short-term continuing resolution that provides fiscal year 2027 appropriations to Federal agencies through December 11, 2026."

What to do if you buy hemp products

None of this is legal advice, and state law can be stricter than federal law in ways this page does not cover — see our state-by-state guide and the federal deadline tracker, which we update as the situation moves.

Practically: the products most exposed to a hard change are THCA flower and prerolls (total-THC test), anything intoxicating sold in a multi-serving container (0.4 mg cap), and converted cannabinoids (delta-8, delta-10, HHC, THC-O), where the date is either contested or unknown. The products least exposed are non-intoxicating CBD, CBG and CBN products that were never near the THC thresholds in the first place.

Whatever you buy between now and December, buy it from a brand that publishes batch-level lab results, because a compliance deadline is exactly the moment when cutting corners becomes tempting. Our guide to reading a COA covers what to actually look at, and how to vet a hemp brand covers the rest of the checklist.

On lab transparency specifically, the best documentation among the brands we cover belongs to CBDfx, which publishes per-strength, per-batch certificates with batch numbers and dates going back to 2020. Medterra uses ISO 17025 labs with QR-code batch lookup, and openly discloses that it does not test for herbicides or glyphosate — a disclosure we would rather have than silence. For a fuller comparison, see our scored ranking of the best CBD and hemp brands for 2026.

FAQ

Is delta-8 banned on 12 November 2026?
We read the statute as moving converted delta-8 to 11 December along with most of the rewrite, because delta-8 is capable of occurring naturally in cannabis even when it is manufactured from CBD. Two practitioner sources read it as staying on 12 November. There is no federal list resolving it, because the FDA never published one. If you need to plan around a date, plan around 12 November.

Is THCA flower affected?
Yes, and this one is not contested. On 11 December 2026 the federal test changes from delta-9 THC alone to total THC, which counts THCA. That is the change that ends the current THCA flower market federally.

What is the 0.4 mg limit?
A cap of 0.4 milligrams per container, effective 11 December 2026, covering the combined total of THC and other cannabinoids with similar effects — not THC alone. The FDA was required to define "container" and has not, which leaves genuine ambiguity about how it applies to multipacks and multi-serving bottles.

Does the delay mean the ban might not happen?
It means the date moved by 29 days and now coincides with a government funding deadline. It does not mean the rewrite has been repealed, weakened, or abandoned. Congress could extend it again, could let it take effect, or could change it substantively. We are not going to predict which.

Is CBD affected?
Ordinary non-intoxicating CBD, CBG and CBN products are largely untouched by the category fight. The 0.4 mg per-container cap does apply to them, so full-spectrum products carrying trace THC in a large container are worth checking; broad-spectrum and isolate products are not near the threshold.

Where does HHC land?
Unresolved. The DEA treats it as synthetic; the statute asks a different question; the FDA has published no list; two federal appeals courts have live challenges pending. Nobody has a defensible date for HHC right now.

Sources and changelog

20 September 2026 — Page published (drafted 7 September; every legal claim re-checked before publication, and the FDA lateness count, the CRS IF13136 passage and the H.R. 9830 link added). Primary sources: H.R. 6500 §2019 statutory text via GovInfo (BILLS-119hr6500eas); 7 U.S.C. §1639o as amended by §781 of division B of Public Law 119-37; Congressional Research Service report IF13136 (version of 17 August 2026, which predates enactment) and Insight IN12620 (3 December 2025); GovInfo bill status for H.R. 6500; Senate Roll Call Votes 227 and 228, 8 August 2026; House Roll Call 286, 1 September 2026; White House briefing record of the 2 September 2026 signing; DEA final rule of 4 May 2026, 91 Fed. Reg. No. 85, Docket DEA-1632 (FR document 2026-08595). Secondary analysis: Perkins Coie; Rod Kight, cannabusiness.law (1 September 2026); Greenspoon Marder (3 September 2026); CannabisRegulations.ai (13 August 2026); Bradley LLP via National Law Review (4 September 2026); Roll Call (24 August 2026).

We will update this page when the FDA publishes the three cannabinoid lists and the "container" guidance, when either circuit court rules on the HHC challenges, and if Congress acts again before 11 December.

Affiliate disclosure: some links on this page are affiliate links and My Cannabis Reviews may earn a commission on purchases made through them, at no additional cost to you. This never affects our rankings, our scores, or our legal analysis. Nothing on this page is legal advice; if you are making commercial decisions about hemp inventory, talk to a lawyer who practises in this area.